Please login to the form below
Calquence
This page shows the latest Calquence news and features for those working in and with pharma, biotech and healthcare.
AZ’s BTK inhibitor Calquence fails in COVID-19 study
AstraZenea’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence has failed to improve survival and prevent respiratory failure in hospitalised COVID-19 patients. ... In a statement, AZ said that the results from the CALAVI trial do not impact the
Latest news
-
AZ strengthens Daiichi Sankyo partnership with new ADC deal
Both cancer types are of particular interest for AZ as it plans to extend its oncology franchise beyond its approved therapies, which include PD-1 inhibitor Imfinzi (durvalumab), lymphoma treatment
-
GSK’s anti-BCMA drug leads crowded CHMP recommendations
AstraZeneca also received two positive opinions following the meeting, with a recommendation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia and a label extension of its PD-1 inhibitor Imfinzi (durvalumab)
-
AZ revenues rise, but it says coronavirus could hit 2020
Recently-approved for a new chronic lymphocytic leukaemia (CLL) indication, AZ’s rival to Johnson &Johnson’s blockbuster BTK inhibitor Imbruvica (ibrutinib) – Calquence (acalabrutinib) – also gathered momentum and contributed $56m in
-
EMA begins review of Kite’s CAR-T for mantle cell lymphoma
Current treatment options for MCL include AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) and Johnson &Johnson/AbbVie’s BTK inhibitor Imbruvica (ibrutinib).
-
BeiGene’s Brukinsa misses the mark in head-to-head Imbruvica trial
The trial was always high-risk, but one that BeiGene was willing to take given that Brukinsa is a third-to-market drug, coming behind Imbruvica and AstraZeneca’s Calquence. ... Imbruvica made over $4bn in sales in the US market alone last year, and
More from news
Approximately 6 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
AstraZeneca: building a new ‘open innovation’ pharma company
AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- bluebird bio’s beti-cel accepted for priority review by FDA
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Booster plans expanded to combat Omicron
- US regulators set to approve oral antiviral against COVID-19
- What does the future hold for Light-chain Amyloidosis?
- As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
- COVID-19 vaccines against Omicron may be fast-tracked
- BMS’ new JAK inhibitor enters regulatory pathways
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- AstraZeneca officially opens new R&D facility in UK
- Biogen hands out $120m upfront for Remedy stroke drug
- China backs use of Roche’s Actemra for coronavirus
PMHub
Oxford PharmaGenesis
Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....
Latest intelligence
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
